CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition

• Published in: International journal of oncology Vol. 59; no. 1; p. 1
• Main Authors: Liao, Yu-Xin, Lv, Ji-Yang, Zhou, Zi-Fei, Xu, Tian-Yang, Yang, Dong, Gao, Qiu-Ming, Fan, Lin, Li, Guo-Dong, Yu, Hai-Yang, Liu, Kai-Yuan
• Format: Journal Article
• Language: English
• Published: Athens Spandidos Publications 01.07.2021; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Adenoviruses; Anthracyclines; Antibodies; Apoptosis; Autophagy; Biochemistry; Biotechnology; Bone cancer; Cancer; Cell death; Chemokines; Chemotherapy; Computer software industry; Drug resistance; Flow cytometry; Investigations; Laboratory animals; Medical prognosis; Metastasis; Osteosarcoma; Plasmids; Proteins; Sarcoma; Transmission electron microscopy; United States; Asia
• ISSN: 1019-6439; 1791-2423
• DOI: 10.3892/ijo.2021.5229

Doxorubicin is one of the most frequently used chemotherapy drugs in the treatment of osteosarcoma (OS), but the emergence of chemoresistance often leads to treatment failure. C-X-C motif chemokine receptor 4 (CXCR4) has been demonstrated to regulate OS progression and metastasis. However, whether CXCR4 is also involved in OS chemoresistance and its molecular mechanisms has yet to be fully elucidated. In the present study, CXCR4-mediated autophagy for OS chemotherapy was investigated by western blot analysis, transmission electron microscopy and confocal microscopy. CXCR4 silencing enhanced doxorubicin-induced apoptosis by reducing P-glycoprotein in CXCR[4.sup.+] LM8 cells, while CXCR4 overexpression promoted OS doxorubicin resistance in CXCR[4.sup.-]Dunn cells. Furthermore, CXCR4 silencing with or without doxorubicin increased the expression of beclin 1 and light chain 3B, and the number of autophagosomes and autolysosomes, as well as induced autophagic fux activation by suppressing the PI3K/AKT/mTOR signaling pathway. In addition, pretreatment with the autophagy inhibitor bafilomycin A1 attenuated CXCR4 abrogation-induced cell death. Finally, the CXCR4 antagonist AMD3100 synergistically reinforced the antitumor effect of doxorubicin in an orthotopic OS mouse model. Taken together, the present study revealed that CXCR4 inhibition sensitizes OS to doxorubicin by inducing autophagic cell death. Therefore, targeting the CXCR4/autophagy axis may be a promising therapeutic strategy to overcome OS chemotherapy resistance.